公开(公告)号：US10206896B2

公开(公告)日：2019-02-19

申请号：US16020517

申请日：2018-06-27

Applicant: KUWAIT UNIVERSITY

Inventor： Milad S. Bitar ,  Fahd Al-Mulla

IPC: C07H21/02 ,  C07H21/04 ,  A61K31/70 ,  A61K31/19 ,  C12N15/113 ,  A61K31/56 ,  C12N5/00

Abstract: The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18α-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

公开(公告)号：US10087487B2

公开(公告)日：2018-10-02

申请号：US14481884

申请日：2014-09-09

Applicant: KUWAIT UNIVERSITY

Inventor： Fahd Al-Mulla ,  Jean Paul Thiery ,  Milad S. Bitar

IPC: C12P19/34 ,  C12Q1/6886

Abstract: The method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer (CRC) can include detecting a level of at least one indicator of metastatic potential in a biological sample from the patient, comparing the level of the indicator of metastatic potential with a control, and identifying the patient as one who is at risk of metastatic relapse and a candidate for chemotherapy if an aberrant level of the indicator of metastatic potential in the biological sample compared to the control is detected. The at least one indicator of metastatic potential can include at least one metastasis-inducing gene and/or at least one metastasis suppressor gene. An aberrant level of the at least one indicator of metastatic potential can include a copy number gain of the metastasis-inducing gene and/or a copy number loss of the metastasis-suppressor gene.

公开(公告)号：US12251366B1

公开(公告)日：2025-03-18

申请号：US18764507

申请日：2024-07-05

Applicant: KUWAIT UNIVERSITY

Inventor： Milad S. Bitar

IPC: A61K31/198 ,  A61P17/02

Abstract: A method of healing a wound in a patient, can include administering to a patient in need thereof a therapeutically effective amount of Sulforaphane-Cysteine (SFN-Cys). The therapeutically effective amount may be 1.5 μM. The SFN-Cys may be combined with an excipient and the excipient may be a poloxamer. The SFN-Cys, combined with a poloxamer, may be applied topically or taken orally.